Genexine, Inc. (095700.KQ)

KRW 5590.0

(-3.79%)

Net Debt Summary of Genexine, Inc.

Genexine, Inc.'s latest annual net debt in 2023 was 61.39 Billion KRW , down -7.18% from previous year.
Genexine, Inc.'s latest quarterly net debt in 2024 Q1 was 66.94 Billion KRW , up 9.05% from previous quarter.
Genexine, Inc. reported annual net debt of 66.14 Billion KRW in 2022, up 170.82% from previous year.
Genexine, Inc. reported annual net debt of 24.42 Billion KRW in 2021, up 11.3% from previous year.
Genexine, Inc. reported quarterly net debt of 68.76 Billion KRW for 2024 Q2, up 2.72% from previous quarter.
Genexine, Inc. reported quarterly net debt of 78.35 Billion KRW for 2023 Q3, up 410.18% from previous quarter.

Annual Net Debt Chart of Genexine, Inc. (2023 - 2012)

Historical Annual Net Debt of Genexine, Inc. (2023 - 2012)

Year	Net Debt	Net Debt Growth
2023	61.39 Billion KRW	-7.18%
2022	66.14 Billion KRW	170.82%
2021	24.42 Billion KRW	11.3%
2020	21.94 Billion KRW	7.96%
2019	20.32 Billion KRW	165.42%
2018	-31.07 Billion KRW	-1031.84%
2017	3.33 Billion KRW	185.03%
2016	-3.92 Billion KRW	48.25%
2015	-7.57 Billion KRW	0.0%
2012	-4.45 Billion KRW	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	66.94 Billion KRW	9.05%
2024 Q2	68.76 Billion KRW	2.72%
2023 Q3	78.35 Billion KRW	410.18%
2023 Q2	15.35 Billion KRW	280.45%
2023 Q1	-8.51 Billion KRW	-112.87%
2023 FY	61.39 Billion KRW	-7.18%
2023 Q4	61.39 Billion KRW	-21.64%
2022 Q2	44.32 Billion KRW	106.62%
2022 Q1	21.45 Billion KRW	-12.15%
2022 FY	66.14 Billion KRW	170.82%
2022 Q4	66.14 Billion KRW	25.44%
2022 Q3	52.72 Billion KRW	18.95%
2021 Q3	19.56 Billion KRW	956.51%
2021 Q4	24.42 Billion KRW	24.81%
2021 FY	24.42 Billion KRW	11.3%
2021 Q1	-3.86 Billion KRW	-117.77%
2021 Q2	-2.28 Billion KRW	40.94%
2020 Q2	12.6 Billion KRW	-66.16%
2020 FY	21.94 Billion KRW	7.96%
2020 Q4	21.77 Billion KRW	1451.87%
2020 Q3	1.4 Billion KRW	-88.87%
2020 Q1	37.24 Billion KRW	84.73%
2019 Q4	20.16 Billion KRW	0.0%
2019 FY	20.32 Billion KRW	165.42%
2018 FY	-31.07 Billion KRW	-1031.84%
2017 FY	3.33 Billion KRW	185.03%
2016 FY	-3.92 Billion KRW	48.25%
2015 FY	-7.57 Billion KRW	0.0%
2013 Q3	10.77 Billion KRW	0.0%
2012 FY	-4.45 Billion KRW	0.0%

Peer Net Debt Comparison of Genexine, Inc.

Name	Net Debt	Net Debt Difference
HLB Co., Ltd.	-46.18 Billion KRW	232.939%
iNtRON Biotechnology, Inc.	-40.58 Billion KRW	251.278%
BINEX Co., Ltd.	45.34 Billion KRW	-35.389%
Bioneer Corporation	-3.9 Billion KRW	1671.109%
Anterogen.Co.,Ltd.	8.35 Billion KRW	-635.12%
MEDIPOST Co., Ltd.	14.81 Billion KRW	-314.435%
CrystalGenomics, Inc.	8.99 Billion USD	-582.788%
Helixmith Co., Ltd	-24.42 Billion KRW	351.356%
Chabiotech Co.,Ltd.	388.94 Billion KRW	84.215%
Medy-Tox Inc.	49.58 Billion KRW	-23.821%
Peptron, Inc.	4.86 Billion KRW	-1161.046%
Amicogen, Inc.	125.26 Billion KRW	50.986%
HLB Therapeutics Co.,Ltd.	-13.68 Billion KRW	548.576%
LegoChem Biosciences, Inc.	-56.05 Billion KRW	209.53%
ALTEOGEN Inc.	53.56 Billion KRW	-14.608%
PharmaResearch Co., Ltd.	-32.93 Billion KRW	286.395%
SillaJen, Inc.	-13.89 Billion KRW	541.963%
JETEMA, Co., Ltd.	84.27 Billion KRW	27.152%
OliX Pharmaceuticals,Inc	27.37 Billion KRW	-124.278%
Genomictree Inc.	-43.43 Billion KRW	241.35%
MedPacto, Inc.	-64 Billion KRW	195.93%
D&D Pharmatech	-7.5 Billion KRW	917.757%
EASY BIO,Inc.	53.21 Billion KRW	-15.382%
GI Innovation, Inc.	-4.82 Billion KRW	1373.106%